CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy

Detalles Bibliográficos
Autores principales: Ramachandran, Raja, Yadav, Ashok K., Kumar, Vinod, Gupta, Krishan L., Kohli, Harbir S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678839/
https://www.ncbi.nlm.nih.gov/pubmed/29142946
http://dx.doi.org/10.1016/j.ekir.2016.08.019
_version_ 1783277522241191936
author Ramachandran, Raja
Yadav, Ashok K.
Kumar, Vinod
Gupta, Krishan L.
Kohli, Harbir S.
author_facet Ramachandran, Raja
Yadav, Ashok K.
Kumar, Vinod
Gupta, Krishan L.
Kohli, Harbir S.
author_sort Ramachandran, Raja
collection PubMed
description
format Online
Article
Text
id pubmed-5678839
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-56788392017-11-15 CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy Ramachandran, Raja Yadav, Ashok K. Kumar, Vinod Gupta, Krishan L. Kohli, Harbir S. Kidney Int Rep Research Letter Elsevier 2016-09-06 /pmc/articles/PMC5678839/ /pubmed/29142946 http://dx.doi.org/10.1016/j.ekir.2016.08.019 Text en . http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Letter
Ramachandran, Raja
Yadav, Ashok K.
Kumar, Vinod
Gupta, Krishan L.
Kohli, Harbir S.
CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
title CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
title_full CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
title_fullStr CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
title_full_unstemmed CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
title_short CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
title_sort cd19 targeted low-dose rituximab is effective in the management of refractory phospholipase a2 receptor antibody-associated membranous nephropathy
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678839/
https://www.ncbi.nlm.nih.gov/pubmed/29142946
http://dx.doi.org/10.1016/j.ekir.2016.08.019
work_keys_str_mv AT ramachandranraja cd19targetedlowdoserituximabiseffectiveinthemanagementofrefractoryphospholipasea2receptorantibodyassociatedmembranousnephropathy
AT yadavashokk cd19targetedlowdoserituximabiseffectiveinthemanagementofrefractoryphospholipasea2receptorantibodyassociatedmembranousnephropathy
AT kumarvinod cd19targetedlowdoserituximabiseffectiveinthemanagementofrefractoryphospholipasea2receptorantibodyassociatedmembranousnephropathy
AT guptakrishanl cd19targetedlowdoserituximabiseffectiveinthemanagementofrefractoryphospholipasea2receptorantibodyassociatedmembranousnephropathy
AT kohliharbirs cd19targetedlowdoserituximabiseffectiveinthemanagementofrefractoryphospholipasea2receptorantibodyassociatedmembranousnephropathy

Ejemplares similares